Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

MS progression is predominantly driven by age-related mechanisms - YES.

Scalfari A.

Mult Scler. 2019 Jun;25(7):902-904. doi: 10.1177/1352458518820633. Epub 2019 Feb 12. No abstract available.

PMID:
30747579
2.

Prognostic information for people with MS: Impossible or inevitable?

Heesen C, Scalfari A, Galea I.

Mult Scler. 2018 Oct 16:1352458518807101. doi: 10.1177/1352458518807101. [Epub ahead of print]

PMID:
30325713
3.

The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.

Scalfari A, Romualdi C, Nicholas RS, Mattoscio M, Magliozzi R, Morra A, Monaco S, Muraro PA, Calabrese M.

Neurology. 2018 Jun 12;90(24):e2107-e2118. doi: 10.1212/WNL.0000000000005685. Epub 2018 May 16.

4.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

5.

Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Nandoskar A, Raffel J, Scalfari AS, Friede T, Nicholas RS.

Drugs. 2017 May;77(8):885-910. doi: 10.1007/s40265-017-0726-0. Review.

PMID:
28429241
6.

The relationship of age with the clinical phenotype in multiple sclerosis.

Scalfari A, Lederer C, Daumer M, Nicholas R, Ebers GC, Muraro PA.

Mult Scler. 2016 Nov;22(13):1750-1758. Epub 2016 Feb 11.

PMID:
26869531
7.

Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NO.

Scalfari A.

Mult Scler. 2015 Oct;21(11):1371-4. doi: 10.1177/1352458515599452. No abstract available.

PMID:
26438304
8.

Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients.

Calabrese M, Reynolds R, Magliozzi R, Castellaro M, Morra A, Scalfari A, Farina G, Romualdi C, Gajofatto A, Pitteri M, Benedetti MD, Monaco S.

PLoS One. 2015 Aug 12;10(8):e0135428. doi: 10.1371/journal.pone.0135428. eCollection 2015.

9.

Mortality in patients with multiple sclerosis.

Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC.

Neurology. 2013 Jul 9;81(2):184-92. doi: 10.1212/WNL.0b013e31829a3388. Review.

10.

Onset of secondary progressive phase and long-term evolution of multiple sclerosis.

Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC.

J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):67-75. doi: 10.1136/jnnp-2012-304333. Epub 2013 Mar 13.

PMID:
23486991
11.

Early relapses, onset of progression, and late outcome in multiple sclerosis.

Scalfari A, Neuhaus A, Daumer M, Deluca GC, Muraro PA, Ebers GC.

JAMA Neurol. 2013 Feb;70(2):214-22. doi: 10.1001/jamaneurol.2013.599.

PMID:
23407713
12.

A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.

Galea I, Lederer C, Neuhaus A, Muraro PA, Scalfari A, Koch-Henriksen N, Heesen C, Koepke S, Stellmann P, Albrecht H, Winkelmann A, Weber F, Bahn E, Hauser M, Edan G, Ebers G, Daumer M.

Eur J Neurol. 2013 Jul;20(7):1107-9. doi: 10.1111/ene.12016. Epub 2012 Dec 7.

13.

Combined MRI lesions and relapses as a surrogate for disability in MS.

Ebers GC, Scalfari A, Daumer M, Lederer C.

Neurology. 2012 Apr 24;78(17):1367; author reply 1367. doi: 10.1212/WNL.0b013e318255b4fe. No abstract available.

PMID:
22529206
14.

Age and disability accumulation in multiple sclerosis.

Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA.

Neurology. 2011 Sep 27;77(13):1246-52. doi: 10.1212/WNL.0b013e318230a17d. Epub 2011 Sep 14.

15.

Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MS.

Ebers GC, Daumer M, Scalfari A.

Neurology. 2011 Mar 15;76(11):1025; author reply 1025-6. doi: 10.1212/WNL.0b013e31820a9674. No abstract available.

PMID:
21403116
16.

Reply to Oluf Anderson's reply: Predicting a window of therapeutic opportunity in multiple sclerosis.

Ebers G, Daumer M, Scalfari A.

Brain. 2011 May;134(Pt 5):e175; author reply e176. doi: 10.1093/brain/awq338. Epub 2011 Feb 8. No abstract available.

PMID:
21303856
17.

Predicting a window of therapeutic opportunity in multiple sclerosis.

Ebers G, Daumer M, Scalfari A.

Brain. 2010 Dec;133(Pt 12):e162; author reply e163. doi: 10.1093/brain/awq226. Epub 2010 Aug 30. No abstract available.

PMID:
20805100
18.

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC.

Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9.

19.

Clinical prognostic factors in multiple sclerosis: a natural history review.

Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC.

Nat Rev Neurol. 2009 Dec;5(12):672-82. doi: 10.1038/nrneurol.2009.178. Review.

PMID:
19953117
20.

Abnormal associative plasticity of the human motor cortex in writer's cramp.

Quartarone A, Bagnato S, Rizzo V, Siebner HR, Dattola V, Scalfari A, Morgante F, Battaglia F, Romano M, Girlanda P.

Brain. 2003 Dec;126(Pt 12):2586-96. Epub 2003 Sep 23.

PMID:
14506068
21.

[Polyorchism: a case report].

Lanza P, Scalfari A, Gemelli R, Pirritano D, Catuogno C, Colosimo MT.

Arch Esp Urol. 1991 Apr;44(3):291-3. Review. Spanish.

PMID:
1867510
22.

Splenic-gonadal fusion in cryptorchidism.

Lanza P, Scalfari A, Docimo C.

Eur Urol. 1987;13(3):210-2. No abstract available.

PMID:
2886339
23.

[Clinical and radiologic contribution to the study of duodeno-choledochal fistulas caused by duodenal ulcer].

Lanza P, Grandinetti R, Scalfari A.

Policlinico Prat. 1967 Aug;74(35):1190-8. Italian. No abstract available.

PMID:
5612872

Supplemental Content

Loading ...
Support Center